MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Clinical trial NCT06128629 · RECRUITING

Trial details

NCT number: NCT06128629
Sponsor: Intellia Therapeutics
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Start date: 2023-12-13
Primary completion: 2027-12-01
Enrollment: 1200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.